
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
When weighing use of systemic therapies for severe atopic dermatitis (AD) physicians must consider potential side effects, such as liver and kidney toxicity and myelosuppression, according to Wynnis L. Tom, M.D.






